Controversies in Hyperkalaemia Management and Practical Approaches
Published: 20 January 2022
Controversy is good. But when it comes to hyperkalaemia management, we need solutions.
Chair, Prof Sydney Tang (University of Hong Kong, HK) Prof Chuan-Ming Hao (Huashan Hospital, CN) and Dr Kieran McCafferty (Queen Mary University London, UK) discuss the implementation of hyperkalaemia management strategies for patients with CKD in line with recent guidelines updates.
The objectives of this educational symposium are to:
- Highlight the burden associated with hyperkalaemia and the impact this has on the use of guideline-directed medical therapy for the treatment of CKD
- Outline the recent updates to KDIGO guidelines around the use of potassium binders to optimise RAASi
- Explain how guideline recommendations can be translated to daily clinical practice
More from this programme
Controversies in Hyperkalaemia Management
New guidelines: Advice for managing RAASi in patients with Hyperkalaemia
Managing Hyperkalaemia in the real world today: A case-based study
Kieran McCafferty is a Consultant Nephrologist at Barts Health NHS Trust and Senior Lecturer and Queen Mary University London. His main clinical interests are diabetic kidney disease and haemodialysis. His basic science research interests are in the field of uraemic cardiovascular disease and cardiovascular protection. However he spends most of his research time developing and delivering clinical trials at both a local and national level. He has a passion for clinical trial delivery having lead on over 40 NIHR clinical trial sin the last 5 years. He is the renal clinical trials lead for Barts Health and the Diabetic Kidney disease Centre, and is the divisional director of research for specialist medicine at Barts Health and the deputy clinical director of R+D in the trust. To help deliver patients focused research across the UK he is the vice chair of the City and East London Ethics committee as well as the North Thames NIHR renal lead and deputy NIHR renal lead.